<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="389">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04475107</url>
  </required_header>
  <id_info>
    <org_study_id>SP-PA-COV-201</org_study_id>
    <nct_id>NCT04475107</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Parallel, Placebo-Controlled, Phase Ⅱ Clinical Trial to Evaluate Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shin Poong Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shin Poong Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center, randomized, double-blind, parallel, placebo-controlled, phase Ⅱ
      clinical trial to evaluate efficacy and safety of Pyramax in mild to moderate COVID-19
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion (%) of patients with virological clearance of SARS-CoV-2 at day 7 post-dose*</measure>
    <time_frame>Day 7</time_frame>
    <description>* Patients who are rRT-PCR negative for COVID-19</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral load reduction of SARS-CoV-2 at Day 3, 7, 10, and 14 post-dose compared to the baseline</measure>
    <time_frame>Day 3, 7, 10, 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion (%) of patients with virological clearance of SARS-CoV-2 at Day 3, 10, and 14 post-dose*</measure>
    <time_frame>Day 3, 10, 14</time_frame>
    <description>* Patients who are rRT-PCR negative for COVID-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in WHO Ordinal Scale for Clinical Improvement at Day 3, 7, 10, 14, and 28 post-dose from the baseline</measure>
    <time_frame>Day 3, 7, 10, 14, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NEWS score at Day 3, 7, 10, 14, and 28 post-dose from the baseline</measure>
    <time_frame>Day 3, 7, 10, 14, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve normalization of body temperature, post-dose</measure>
    <time_frame>Day 3, 7, 10, 14, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve normalization of respiratory rate, post-dose</measure>
    <time_frame>Day 3, 7, 10, 14, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve normalization of oxygen saturation, post-dose</measure>
    <time_frame>Day 3, 7, 10, 14, 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pyramax (Pyronaridine 180mg/ Artesunate 60mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyronaridine-Artesunate</intervention_name>
    <description>Pyramax</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥19 years at the time of signing Informed Consent Form

          2. Body weight ≥45 kg at screening

          3. Laboratory (rRT-PCR) confirmed infection with SARS-CoV-2 by testing specimens from
             upper airway (i.e. nasopharyngeal and oropharyngeal swab) or lower airway (i.e.
             sputum) within 72 hours of randomization

          4. Oxygen saturation(SpO2) &gt; 94% at randomization, in room air condition

          5. Willing and able to provide informed consent

        Exclusion Criteria:

          1. Diagnosed with severe pneumonia

          2. Patients with clinically significant cardiovascular disease (including arrhythmia, QTc
             interval prolongation)

          3. Patients with clinically significant anemia (Hemoglobin &lt;8.0 g/dL)

          4. Patient with known allergic reaction or contraindication to any of the investigational
             medicinal product (pyronaridine tetraphosphate, artesunate)

          5. Patients with known history of galactose intolerance, Lapp lactase deficiency or
             glucose-galactose malabsorption, etc.

          6. Patients with the gastrointestinal disease and surgery to affect the absorption,
             distribution, metabolism and excretion of the drug, active gastritis, gastrointestinal
             tract / rectal bleeding, gastric ulcer, pancreatitis abnormalities (except simple
             appendectomy or hernia surgery)

          7. Patients who received antiviral drugs that is intended to treat COVID-19, within 28
             days prior to screening evaluation (can be enrolled into the study, if the patient has
             gone through a sufficient wash-out period)

          8. Patients with known severe renal impairment (estimated glomerular filtration rate ≤30
             mL/min/1.73 m2)

          9. Patients with known severe liver disease (i.e. ALT or AST&gt;5 times upper limit, nausea,
             abdominal pain associated with jaundice or Child-Pugh stage B or C)

         10. Viral disease (HIV, HBV, HCV, etc.) other than COVID-19 that require administration of
             other antiviral agents

         11. Patients that require ventilation therapy (e.g. non-invasive ventilation, invasive
             mechanical ventilation, extracorporeal membrane oxygenation, etc.)

         12. Patients with chronic underlying disease (e.g. uncontrolled diabetes mellitus, chronic
             kidney disease, chronic liver disease, chronic pulmonary disease, chronic
             cardiovascular disease, blood cancer, cancer patients with cancer treatment, patients
             taking immunosuppressants), highly obese patients, dialysis patients, and transplant
             patients that are determined by the Physician, to be not suitable for trial
             involvement.

         13. Pregnant or lactating women

         14. Male or female of childbearing potential who has plans to become pregnant during the
             study period and for three months after the clinical study or who is not willing to
             take appropriate contraceptive measures

             *Hormonal contraception (contraceptive implant, injections, pills, etc.), IUDs,
             condoms (male) and contraceptive diaphragm or cap (female), sterilization (vasectomy,
             tubal ligation, etc.)

         15. Participating in another clinical trial currently or within 28 days from signing the
             informed consent

         16. Patients that are deemed ineligible to participate in the clinical trial by the
             Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kim</last_name>
    <phone>jdkim@shinpoong.co.kr</phone>
    <email>jdkim@shinpoong.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hallym University Kangnam Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyungpook national university hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>July 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2020</study_first_posted>
  <last_update_submitted>July 28, 2020</last_update_submitted>
  <last_update_submitted_qc>July 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pyramax</keyword>
  <keyword>Pyronaridine</keyword>
  <keyword>Artesunate</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Corona virus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Pyronaridine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

